Cripto-1 antibody (Internal Region)

Catalog No. ABIN233828

Product Details anti-Cripto-1 Antibody

Target: Cripto-1 (TDGF1.3) (Teratocarcinoma-Derived Growth Factor 1, Member 3 (TDGF1.3))

Binding Specificity: Internal Region

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Cripto-1 antibody is un-conjugated

Application: ELISA, Western Blotting (WB)

Characteristics: Concentration Definition: by UV absorbance at 280 nm

Immunogen: This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to an sequence of human Cripto-1 protein.

Isotype: IgG

Application Details

Application Notes: This affinity purified antibody has been tested for use in ELISA and western blotting.  Specific conditions for reactivity should be optimized by the end user.  Expect a band approximately 21 kDa in size corresponding to Cripto-1 by western blotting in the appropriate cell lysate or extract.  Cripto-1 is reported as a 188 amino acid protein with a molecular weight of 21.1 kDa.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.66 mg/mL

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

References for anti-Cripto-1 antibody (ABIN233828)

Ligtenberg, Witt, Galvez-Cancino, Sette, Lundqvist, Lladser, Kiessling: "Cripto-1 vaccination elicits protective immunity against metastatic melanoma." in: Oncoimmunology, Vol. 5, Issue 5, pp. e1128613, (2016) (PubMed).

Strizzi, Margaryan, Gerami, Haghighat, Harms, Madonna, Botti, Ascierto, Hendrix: "Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi." in: Oncology letters, Vol. 12, Issue 2, pp. 1349-1354, (2016) (PubMed).

Tysnes, Satran, Mork, Margaryan, Eide, Petersen, Strizzi, Hendrix: "Age-Dependent Association between Protein Expression of the Embryonic Stem Cell Marker Cripto-1 and Survival of Glioblastoma Patients." in: Translational oncology, Vol. 6, Issue 6, pp. 732-41, (2014) (PubMed).

Strizzi, Margaryan, Gilgur, Hardy, Normanno, Salomon, Hendrix: "The significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics." in: Cell cycle (Georgetown, Tex.), Vol. 12, Issue 9, pp. 1450-6, (2013) (PubMed).

Malchenko, Galat, Seftor, Vanin, Costa, Seftor, Soares, Hendrix: "Cancer hallmarks in induced pluripotent cells: new insights." in: Journal of cellular physiology, Vol. 225, Issue 2, pp. 390-3, (2010) (PubMed).

Target Details for Cripto-1

Target: Cripto-1 (TDGF1.3) (Teratocarcinoma-Derived Growth Factor 1, Member 3 (TDGF1.3))

Alternative Name: Cripto-1 TDGF1 (TDGF1.3 Products)

Background: This antibody is designed, produced, and is suitable for Cancer, Immunology and Nuclear Signaling research. Human Cripto-1 (CR-1), also known as Teratocarcinoma-derived growth factor 1 (TDGF1), is a member of the epidermal growth factor (EGF)-GFC family and has been implicated in both embryogenesis and carcinogenesis.  During early vertebrate development, CR-1 functions as a co-receptor for Nodal, a transforming growth factor b (TGFb) family member, and is essential for mesoderm and endoderm formation and anterior-posterior and left-right axis establishment.  In adult tissues, CR-1 is expressed at a low level in all stages of mammary gland development, and expression increases during pregnancy and lactation.  Over-expression of CR-1 in mouse mammary epithelial cells leads to their transformation in vitro, and when injected in mammary glands, CR-1 produces ductal hyperplasias.
Synonyms: Cripto1 antibody, Cripto1 growth factor antibody, Epidermal growth factor like cripto protein CR1 antibody, TDGF 1 antibody

Gene ID: 6997, 4507425

UniProt: P13385